新AACE糖尿病临床实践指南

2011-06-13 刘秋阳 中国医学论坛报

     2011年4月14日,布卢姆加登(Bloomgarden)教授主持了题为《AACE-糖尿病临床实践指南》的专题报告会。在会上,AACE候任主席、AACE糖尿病指南写作委员会联合主席、该指南的主笔人汉德尔斯曼教授,对新指南进行了详解。   汉德尔斯曼教授谈到,根据美国疾病预防控制中心(CDC)2011年1月26日的报告,有近2600万美国人患糖尿病,7900万人有糖尿病前期表现。如果持

     2011年4月14日,布卢姆加登(Bloomgarden)教授主持了题为《AACE-糖尿病临床实践指南》的专题报告会。在会上,AACE候任主席、AACE糖尿病指南写作委员会联合主席、该指南的主笔人汉德尔斯曼教授,对新指南进行了详解。   汉德尔斯曼教授谈到,根据美国疾病预防控制中心(CDC)2011年1月26日的报告,有近2600万美国人患糖尿病,7900万人有糖尿病前期表现。如果持续目前的趋势,则3个美国人当中就将有1人在其一生中发生糖尿病。   与未患糖尿病者相比,被诊断为糖尿病者医疗花费将增加2.3倍,并将不可避免地发生各种并发症、残疾和早产儿死亡。而通过与相关支持网络和健康保健专业人员合作,糖尿病患者可通过控制血糖、血压和血脂,并及时接受其他预防性治疗来防止早产儿死亡和残疾。   新指南目的、内容及意义 新指南是对此前发布指南的补充和扩展,目的是为临床内分泌医师及其他关注糖尿病患者的临床医师提供教育资源。新指南提倡采取综合性治疗措施,并建议临床医师,应超越对血糖控制的单纯关注。此外,新指南还提供了各种糖尿病治疗方法的证据级别及在临床实践中可使用的电子化文件,

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1699171, encodeId=1a8816991e132, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Fri May 11 17:14:00 CST 2012, time=2012-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655635, encodeId=116216556356f, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Nov 25 02:14:00 CST 2011, time=2011-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030959, encodeId=46132030959eb, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sun Jul 24 08:14:00 CST 2011, time=2011-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323575, encodeId=15e413235e5a9, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Wed Jun 15 11:14:00 CST 2011, time=2011-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571909, encodeId=2d9615e1909ec, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Wed Jun 15 11:14:00 CST 2011, time=2011-06-15, status=1, ipAttribution=)]
    2012-05-11 zgwhgch
  2. [GetPortalCommentsPageByObjectIdResponse(id=1699171, encodeId=1a8816991e132, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Fri May 11 17:14:00 CST 2012, time=2012-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655635, encodeId=116216556356f, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Nov 25 02:14:00 CST 2011, time=2011-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030959, encodeId=46132030959eb, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sun Jul 24 08:14:00 CST 2011, time=2011-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323575, encodeId=15e413235e5a9, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Wed Jun 15 11:14:00 CST 2011, time=2011-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571909, encodeId=2d9615e1909ec, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Wed Jun 15 11:14:00 CST 2011, time=2011-06-15, status=1, ipAttribution=)]
    2011-11-25 shanyongle
  3. [GetPortalCommentsPageByObjectIdResponse(id=1699171, encodeId=1a8816991e132, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Fri May 11 17:14:00 CST 2012, time=2012-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655635, encodeId=116216556356f, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Nov 25 02:14:00 CST 2011, time=2011-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030959, encodeId=46132030959eb, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sun Jul 24 08:14:00 CST 2011, time=2011-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323575, encodeId=15e413235e5a9, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Wed Jun 15 11:14:00 CST 2011, time=2011-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571909, encodeId=2d9615e1909ec, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Wed Jun 15 11:14:00 CST 2011, time=2011-06-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1699171, encodeId=1a8816991e132, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Fri May 11 17:14:00 CST 2012, time=2012-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655635, encodeId=116216556356f, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Nov 25 02:14:00 CST 2011, time=2011-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030959, encodeId=46132030959eb, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sun Jul 24 08:14:00 CST 2011, time=2011-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323575, encodeId=15e413235e5a9, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Wed Jun 15 11:14:00 CST 2011, time=2011-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571909, encodeId=2d9615e1909ec, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Wed Jun 15 11:14:00 CST 2011, time=2011-06-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1699171, encodeId=1a8816991e132, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Fri May 11 17:14:00 CST 2012, time=2012-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655635, encodeId=116216556356f, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Nov 25 02:14:00 CST 2011, time=2011-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030959, encodeId=46132030959eb, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sun Jul 24 08:14:00 CST 2011, time=2011-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323575, encodeId=15e413235e5a9, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Wed Jun 15 11:14:00 CST 2011, time=2011-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571909, encodeId=2d9615e1909ec, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Wed Jun 15 11:14:00 CST 2011, time=2011-06-15, status=1, ipAttribution=)]

相关资讯

FGF-21:下一个抗糖尿病新药?

 冯文科,美国华人糖尿病学会(CADA)会员,美国路易斯维尔大学医学院助理教授。美国心脏学会(AHA)、美国糖尿病学会(ADA)及药理和实验治疗学会会员。担任AHA基金评   审人及多种学术期刊的审稿人和述评人。研究曾获得ADA、美国国立卫生研究院(NIH)及肯塔基州政府的资助。   刘彦隆,温州医学院和路易斯维尔大学联合培养博士研究生。   FGF-21的作用机制   成纤维细胞生长

新诊断2型糖尿病患者的药物治疗及专家点评

   病例简介   一般情况:患者男性,49岁,病史2个月。以口干、多饮、多尿、体重下降伴乏力等症状起病,发现尿糖阳性1天来诊。平素体健,活动少,多食用高脂饮食,吸烟史20年,20支/日,无高血压、冠心病等慢性疾患。其母患糖尿病。   查体:身高173 cm,体重81.0 kg, 体质指数(BMI) 27.06 kg/m2,血压130/85&

FDA批准2型糖尿病治疗新药DPP-4抑制剂Linagliptin

  2011年5月2日,美国食品与药物管理局(FDA)发布公告,批准Tradjenta(活性成分linagliptin)片剂结合运动与饮食控制一起,用于改善成人2型糖尿病患者的血糖控制。   2型糖尿病患者体内不产生胰岛素或对胰岛素失去正常反应。胰岛素是一种调节血液中葡萄糖含量的激素。随着时间推移,高血糖水平会增加严重并发症的风险,包括心脏病、失明、神经和肾脏受损。   2型糖尿病是糖尿病最常

合并肝硬化的糖尿病性肌坏死:病例报告及文献综述

    Angervall和Stener于1965年首次报道了糖尿病性肌肉坏死[1]。其发病常见于1型糖尿病伴有长期代谢紊乱与晚期慢性微血管并发症的患者。典型的临床表现为受累部位肌肉部位(通常是股四头肌)突剧烈疼痛。磁共振成像(MRI)可确诊。在不能确诊的情况下,可能需要进行肌肉活组织检查。糖尿病性肌肉坏死的治疗包括卧床休息、止痛和改善糖尿病代谢。本病预后差,且预示着

ARD:类风湿关节炎患者心梗风险与糖尿病患者相当

  ■研究内容   丹麦学者研究发现,类风湿关节炎(RA)患者心梗(MI)风险与糖尿病(DM)患者及年长10岁的非RA人群相当。论文发表于即将出版的《风湿病年鉴》6月期 [Ann Rheum Dis, 2011, 70(6):929]。   研究纳入431万余名研究对象,包括10477例RA患者和130215例DM患者。   结果显示,MI的总发病率比(IRR)在RA患者与DM患者中均为1.

Diabetes:糖基化LDL致AS作用增强

 英国学者的一项研究表明,丙酮醛(MG)修饰低密度脂蛋白(LDL)可形成小而致密的LDL,其致动脉粥样硬化(AS)作用增强。这可能对糖尿病心血管风险递增和二甲双胍的心脏保护作用做出了解释。论文于2011年5月26日在线发表于《糖尿病》(Diabetes)杂志。   研究者分离出人类LDL并且在体外通过MG最低限度修饰LDL(MGmin-LDL)。研究者对MGmin-LDL的致动脉粥样硬化特征进行